Tirzepatide

Tirzepatide serves as a groundbreaking 39-amino acid modified peptide, functioning as a selective agonist for both the glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors. By integrating these two physiological pathways, the compound offers a high-precision model for studying synergistic metabolic regulation and incretin system homeostasis.

Analytical verification via LC-MS ensures a purity profile exceeding 99.4%, confirming the absence of diastereomeric impurities that could compromise quantitative research data. Advanced peptide stabilization techniques are applied during the vacuum-drying process to maintain the alpha-helical structural integrity, resulting in a robust lyophilized unit optimized for standardized laboratory reconstitution.